small article i found on the latest news:
http://www.4-traders.com/PROMETIC-LIFE-SCIENCES-IN-1411267/news/ProMetic-Life-Sciences--Finalizes-PBI-4050-Phase-I-Clinical-Trial-18644770/
ProMetic Life Sciences : Finalizes PBI-4050 Phase I Clinical Trial
06/26/2014 | 12:46am US/Eastern
Recommend:
ProMetic Life Sciences reported that it has completed its PBI- 4050 Phase I clinical trial in 40 healthy volunteers.
In its release on June 18, the Company said that ProMetic's PBI- 4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the five cohorts tested.
The objectives of this oral, double blind, placebo controlled, single ascending dose study were to demonstrate the safety and tolerability of PBI-4050 and to establish the pharmacokinetic profile of the drug candidate at different doses.
The study design also included a component looking at food effect on drug absorption. The trial was conducted in five cohorts of eight subjects. In each cohort, six subjects received PBI-4050 and two subjects received matching placebo.
"This bodes very well for the clinical program as the therapeutic dose is expected to be at the low end of the range tested in this clinical trial," said John Moran, Chief Medical Officer of ProMetic. "With this excellent safety profile, we can now test this very promising drug candidate in patients."
"PBI-4050 is now set to move into clinical development in diabetic patients with kidney diseases, as well as other orphan medical conditions where diabetes and/or fibrosis is affecting key organs such as liver, kidney, heart and lungs. We will disclose such selected additional indications over the coming months," said Pierre Laurin, President and Chief Executive Officer of ProMetic.